Asset
ZELECIMENT BASIVARSEN
DYNE THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07486934 | phase3 | recruiting | 2026-05-14 | 2028-07-01 | Dyne Therapeutics | Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 |
| NCT05481879 | phase1_2 | active_not_recruiting | 2022-09-05 | 2029-07-01 | Dyne Therapeutics | Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 |
FDA applications (0)
This company has no applications containing this asset.